UT MD Anderson Cancer Center Hematopathology Update Series 2026 Course: Integration of Flow Cytometry in Diagnostic Hematopathology

---

LIVE

Saturday, September 19, 2026, 8:00 AM - Sunday, September 20, 2026, 5:00 PM, MD Anderson - Zayed, Houston, TX


AMA PRA Category 1 Credits™ (10.75 hours), ABPath MOC Part II (10.75 hours), Non-Physician Attendance (10.75 hours)

This course offers a practical update in contemporary hematopathology, emphasizing the integration of flow cytometry into diagnostic workflows. Through focused lectures and interactive case-based discussions, participants will learn how flow cytometry informs diagnosis and differential diagnosis, address common and challenging diagnostic scenarios, review emerging applications, and identify important diagnostic pitfalls.

1. Compare the key immunophenotypic features of myeloid and lymphoid neoplasms.
2. Apply flow cytometry in the differential diagnosis of entities with overlapping features.
3. Recognize technical artifacts and common diagnostic pitfalls.

Registration closes on August 31, 2026.

* Breakfast on Friday and Saturday, as well as lunch and dinner on Friday, are included.

You are invited to submit an interesting and challenging lymphoma and leukemia cases with flow cytometry contributing to the diagnosis. The deadline for case submission is July 15, 2026, and the notification of submission status will be August 15, 2026. 

Please click here to submit a case.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Pathology MOC Credit:

This activity has been registered to offer credit in the American Board of Pathology’s Continuing Certification program. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.75 Lifelong Learning credits. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit.

View the accessibility policy for The University of Texas MD Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the educational content of a certified continuing education (CE) activity, including faculty, planners, reviewers, are required to disclose all financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used on or by patients. All relevant financial relationships have been mitigated prior to the start of the activity.